Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics Limited has requested a voluntary suspension of its securities from the Australian Securities Exchange (ASX) pending an announcement related to a capital raising. The suspension follows a previous trading halt due to the limited availability of investors during the reporting season. This move is anticipated to impact the company’s financial strategy and market operations as it seeks non-dilutionary funding.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.
Average Trading Volume: 4,603,630
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.37M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.